ADAPTABLE is a clinical trial comparing the effectiveness of 81mg versus 325mg daily doses of aspirin to prevent heart attack and stroke in people living with heart disease. Results are now available on the study website. The nonprofit Clinical Research Forum selected the PCORI-funded ADAPTABLE—the first large-scale study of aspirin dosing to be embedded in real-world practice—to receive one of its 2022 Top Ten Clinical Research Achievement Awards.